AI is one of the hottest topics in pharma at the moment and is already starting to yield results. One area it is making significant impact is in R&D. In the last two years alone there have been several multi million pound deals with leading pharma companies and AI providers, one of the most recent being the GSK collaboration with Cloud Pharmacuticals, who we interviewed earlier this month. R&D has always been a strong area for Novasecta and given our expertise MedNous asked us to think about how pharma companies could approach AI in R&D.

For insight on what the wider pharma industry should do about AI click here

To view our content please complete the form below and submit





 

Please click submit and wait for the page to refresh

It is widely believed that a product’s trajectory in the first six months is predictive of long- term performance but Ed Corbett opines, in the latest issue of Pharmaceutical Market Europe (PME), that the 36 months before launch will dictate performance.

To read the full article click here

Newsletter Signup